



HUA MEDICINE

華領醫藥

*(Incorporated in Cayman Islands with limited liability)*

(Stock Code: 2552)

27 June 2024

Dear Shareholders

### **New Arrangements on Dissemination of Corporate Communications**

#### **INTRODUCTION**

Pursuant to new Rule 2.07A<sup>1</sup> of the Rules (the “Listing Rules”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and the articles of association of Hua Medicine (the “Company”), the Company will disseminate the future corporate communications of the Company (the “Corporate Communications”<sup>2</sup>) to its Shareholders<sup>3</sup> electronically and only send Corporate Communications in printed form to the Shareholders upon request.

In this connection, the following arrangements has come into effect.

#### **ARRANGEMENTS**

1. Actionable Corporate Communications<sup>4</sup>

The Company will send the Actionable Corporate Communications to its Shareholders individually in electronic form by email. If the Company does not possess the email address of a Shareholder or the email address provided is not functional<sup>5</sup>, the Company will send the Actionable Corporate Communications in printed form together with a request form for soliciting the Shareholder’s functional email address to facilitate electronic dissemination of Actionable Corporate Communications in the future.

## 2. Corporate Communications

The Company will make the Corporate Communications available on its website ([www.huamedicine.com](http://www.huamedicine.com)) and the Stock Exchange's website ([www.hkexnews.hk](http://www.hkexnews.hk)).

A notice of publication of the Website Version<sup>6</sup> of Corporate Communications, in both English and Chinese, will be sent by the Company to Shareholders by email or by post (only if the Company does not possess the functional email address of a Shareholder) on the publication date of the Corporate Communications.

## 3. Provision of Shareholder's Email Address to the Company

In support of electronic communication by email, the Company recommends its Shareholders to complete the online form by scanning the QR Code above, which is valid until 26 August 2024. Should the Shareholders, if for any reason, have difficulty in gaining access to the online form, they may provide the Company with their email address at any time in future by reasonable notice in writing to the Company's share registrar in Hong Kong at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong or by email to [2552-ecom@hk.tricorglobal.com](mailto:2552-ecom@hk.tricorglobal.com).

It is the responsibility of the Shareholders to provide email address that is functional. If the Company does not possess the email address of a Shareholder or the email address provided is not functional, the Company will act according to the above arrangements. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any "non-delivery message".

## 4. Request for Corporate Communications and Actionable Corporate Communications in printed form

For those Shareholders who wish to receive a printed version of all future Corporate Communications and Actionable Corporate Communications) or, if for any reason, have difficulty in gaining access to the Company's website, the Company will, upon receipt of request in writing by the Shareholder to the Company's share registrar in Hong Kong at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong or by email to [2552-ecom@hk.tricorglobal.com](mailto:2552-ecom@hk.tricorglobal.com), send future Corporate Communications and/or the relevant Corporate Communications (as the case may be) to such Shareholders in printed form free of charge.

Details of the arrangements (i) for dissemination of Corporate Communications and (ii) for requesting printed copy of Corporate Communications are published under the "Investor Relations" section in the Company's website ([www.huamedicine.com](http://www.huamedicine.com)). For any queries in relation to this letter, please call the Company's share registrar in Hong Kong, Tricor Investor Services Limited, at +852 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays, or by sending an email to [2552-ecom@hk.tricorglobal.com](mailto:2552-ecom@hk.tricorglobal.com).

<sup>1</sup> With effect from 31 December 2023.

<sup>2</sup> Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) the quarterly report, if any; (d) a notice of meeting; (e) a listing document; (f) a circular; and (g) a proxy form.

<sup>3</sup> Holder(s) of the Share(s) of the Company.

<sup>4</sup> Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as the Company's Shareholders.

<sup>5</sup> It is the responsibility of a Shareholder to provide email address that is functional. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any "non-delivery message".

<sup>6</sup> The version of Corporate Communications being published, in both English and Chinese (where applicable), on the Company's website.

By the order of the Board

**Hua Medicine**

**Dr. Li Chen**

Chief Executive Officer and Executive Director